Shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX – Get Rating) have been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $22.67.
Several research firms have commented on MDRX. StockNews.com began coverage on Allscripts Healthcare Solutions in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Piper Sandler reissued an “overweight” rating and issued a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Friday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of Allscripts Healthcare Solutions from $19.00 to $20.00 and gave the stock an “underweight” rating in a research note on Friday, November 18th. The Goldman Sachs Group upgraded shares of Allscripts Healthcare Solutions from a “neutral” rating to a “buy” rating and increased their target price for the company from $22.00 to $23.00 in a research report on Tuesday, November 8th. Finally, TheStreet upgraded shares of Allscripts Healthcare Solutions from a “c+” rating to a “b-” rating in a research report on Wednesday, November 30th.
In other Allscripts Healthcare Solutions news, CEO Richard J. Poulton sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $18.14, for a total value of $181,400.00. Following the transaction, the chief executive officer now directly owns 722,517 shares in the company, valued at approximately $13,106,458.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Tejal Vakharia sold 8,642 shares of the stock in a transaction on Monday, December 12th. The stock was sold at an average price of $18.42, for a total transaction of $159,185.64. Following the completion of the transaction, the senior vice president now directly owns 222,604 shares in the company, valued at approximately $4,100,365.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Richard J. Poulton sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $18.14, for a total transaction of $181,400.00. Following the completion of the sale, the chief executive officer now owns 722,517 shares in the company, valued at $13,106,458.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,776 shares of company stock valued at $1,137,271. 2.29% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. CWM LLC grew its stake in shares of Allscripts Healthcare Solutions by 578.4% in the third quarter. CWM LLC now owns 2,103 shares of the software maker’s stock valued at $32,000 after buying an additional 1,793 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new position in Allscripts Healthcare Solutions in the 3rd quarter valued at about $33,000. Robeco Institutional Asset Management B.V. acquired a new position in Allscripts Healthcare Solutions in the 3rd quarter valued at about $93,000. MQS Management LLC purchased a new stake in Allscripts Healthcare Solutions during the second quarter worth about $154,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Allscripts Healthcare Solutions during the second quarter worth about $156,000. Hedge funds and other institutional investors own 99.76% of the company’s stock.
Allscripts Healthcare Solutions Stock Down 1.3 %
Shares of MDRX opened at $17.64 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.93 billion, a P/E ratio of 41.02, a PEG ratio of 1.64 and a beta of 1.01. The stock’s 50 day moving average is $17.46 and its two-hundred day moving average is $16.38. Allscripts Healthcare Solutions has a 12 month low of $13.59 and a 12 month high of $23.25.
Allscripts Healthcare Solutions (NASDAQ:MDRX – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The software maker reported $0.20 EPS for the quarter, topping the consensus estimate of $0.15 by $0.05. Allscripts Healthcare Solutions had a net margin of 7.25% and a return on equity of 10.74%. The company had revenue of $151.90 million during the quarter, compared to analyst estimates of $152.79 million. During the same quarter in the previous year, the firm earned $0.21 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. Analysts predict that Allscripts Healthcare Solutions will post 0.68 earnings per share for the current fiscal year.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc, together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Allscripts Healthcare Solutions, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Allscripts Healthcare Solutions wasn’t on the list.
While Allscripts Healthcare Solutions currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here